1. Kapur A, O’Connor-Semmes R, Hussey EK, et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013;14(26):1–11.
2. Glenmark Pharmaceuticals. Glenmark launches novel, globally-researched anti-diabetes drug remogliflozin in India [media release]. 30 Apr 2019.
https://www.prnewswire.com/in/news-releases/glenmark-launches-novel-globally-researched-anti-diabetes-drug-remogliflozin-in-india-806614073.html
.
3. Wilkison B, Cheatham B, Walker S. Remogliflozin etabonate reduces FIB-4 and NAFLD fibrosis scores in type 2 diabetic subjects [abstract no. 1087]. Hepatology. 2016;64(1 Suppl.):548A.
4. Glenmark Pharmaceuticals. Remogliflozin etabonate 100 mg tablets: proposed summary of product characteristics. 2019.
5. Sykes AP, O’Connor-Semmes R, Dobbins R, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(1):94–7.